Press releases

  • Antibodies open a treatment option for patients who are already infected with SARS-CoV-2. The Braunschweig-based Division of Pharmaceutical Biotechnology of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, in collaboration with Corat Therapeutics GmbH, will begin production of a specific SARS-CoV-2 antibody that is expected to enter clinical trials as early as the beginning of 2021.

    more info
  • New treatments in the fight against cancer / 2020

    Hunting down life-threatening metastases

    Research News / June 02, 2020

    What makes tumor cells turn murderous? The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is investigating the mechanisms of metastasis formation – and searching for approaches for new treatments in the fight against cancer. Among other things, the research team at Fraunhofer ITEM has developed a method that enables them to analyze entire lymph nodes.

    more info
  • With its rapid spread around the world, the new coronavirus SARS-CoV-2 has triggered a public health emergency of international concern. To date, there is neither a vaccine nor drugs for treating COVID-19 patients available. Researchers of the international consortium iCAIR® are working on the development of novel anti-infective agents to treat or prevent clinically significant diseases of the respiratory tract caused by viruses, fungi and bacteria – and they recently started a project aimed at developing medications to combat the coronavirus SARS-CoV-2.

    more info
  • New agents to fight multidrug-resistant germs

    Research News / January 02, 2020

    Resistance to antibiotics is on the rise worldwide. Fraunhofer scientists have joined forces with partners in the Phage4Cure project to explore alternatives to antibiotics. One objective is to vanquish multidrug-resistant pathogens with viruses called bacteriophages. Another is to see these phages approved to treat the dreaded hospital germ Pseudomonas aeruginosa, the most frequent bacterial cause of pneumonia.

    more info
  • Fighting infections and resistances

    Press release / December 04, 2019

    Winter is influenza season. In the northern hemisphere, cases of this infectious disease peak between November and March, and fatalities are not uncommon. Influenza vaccines can protect against the illness, but they aren’t always effective. According to the Robert Koch Institute, the vaccines for 2018/2019 were only about 20 percent effective. In the iCAIR® project, Fraunhofer researchers are collaborating with partners to develop new, urgently needed agents against influenza, as well as against other infectious diseases that are gaining ground worldwide. What is particularly interesting here is that the research team at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM can test the anti-infective agents in vital human lung slices.

    more info
  • Funded with 8.3 million euros over a period of five years, a platform shall be developed to support small and medium-sized manufacturers of medical devices in the conformity assessment of their products. This will include development of three demonstrator technologies in the fields of inhalers, neural implants, and coatings for hip replacement implants.

    more info
  • Fraunhofer ITEM is participating in the EU project TBMED to support European small and medium-sized med-tech companies / 2019

    Open-innovation test bed for medical devices

    Press release / March 21, 2019

    Aiming to support European med-tech companies in the global competition, the EU has initiated the project TBMED – An Open-Innovation Test Bed for the Development of High-Risk Medical Devices. Together with 12 project partners from Spain, France, Ireland and Germany, Fraunhofer ITEM is actively participating in the development of a test bed for medical devices of risk classification IIb and higher. The project will receive 8.5 million euros funding under the European Union’s Horizon 2020 Framework Program and will run until the end of February 2023.

    more info
  • Translational biomedical engineering: Intelligent inhalation system / 2018

    Gentle treatment for premature babies with lung diseases

    Press release / December 10, 2018

    Premature babies who are born before their lungs have finished maturing often suffer from a lack of surfactant – a substance necessary for lung development. They are also particularly susceptible to illnesses of the respiratory organ, which have to be treated by means of inhalation. However, the inhalation systems available are not geared to the needs of preterm infants and newborns. Researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM are working with partners to develop a system that would allow drugs to be administered as aerosols in an efficient and breath-triggered manner. This would shorten therapy duration, thereby easing the strain on little bodies.

    more info